Arduan

(pipecuronium bromide)

ApprovedSmall molecule

OOrganon and Co

Arduan is one of 4 small molecule programs targeting Neuromuscular Blockade. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Neuromuscular BlockadeNot yet recruiting

Neuromuscular BlockadeApproved

Not yet recruiting

Competition

Competitive Landscape

7 competitors in Neuromuscular Blockade

#DrugCompanyPhaseTrials

Arduan

OOrganon and Co

Approved

2 2

HRS-9190

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

1 3

Conventional Dose CRRT

SSeoul National University Hospital

Preclinical

1 4

Profound Neuromuscular Blockade

SSheba Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Post-ApprovalActive, not recruiting

Neuromuscular Blockade

NCT07044180

Post-ApprovalNot yet recruiting

Neuromuscular Blockade

NCT07044193

Clinical

Trials by Indication[1]

Neuromuscular Blockade2 trials

Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Propofol Anesthesia

Active, not recruiting·TTamas Vegh, MD·Phase 4·NCT07044180·80 enrolled

Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Sevoflurane Anesthesia

Not yet recruiting·TTamas Vegh, MD·Phase 4·NCT07044193·80 enrolled

Regulatory

FDA Approval Timeline[4]

Jun 26, 1990

ARDUAN

NDA NDA019638

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for pipecuronium bromide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pipecuronium bromide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pipecuronium bromide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA019638). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Organon and Co company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: OOrganon and Co

Arduan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Neuromuscular Blockade2 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News